English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Due to an error in the final stages of production, we regret that the fifth paragraph in the above manuscript was printed incorrectly. The complete, corrected paragraph is reprinted below. ''The strong recommendation made by the authors is that the press release should be proactively discussed with all patients with definite or probable IPF, currently receiving immunosuppressive therapy, in order to make a shared decision on subsequent management. Over and above a review of the press release itself, informed discussion should include a summary of the aforementioned uncertainties and detailed consideration of the specific clinical scenario of the individual patient. We recommend strongly that the patient should be offered the opportunity to take a view on management changes and, in clinical scenarios in which management decisions are otherwise a close call, strongly held views of the patient should determine the final management decision.''

european respiratory journal/the european respiratory journal

“Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” A.U. Wells, J. Behr, U. Costabel, V. Cottin and V. Poletti.<i>Eur Respir J</i>2012; 39: 805–806.

“Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” A.U. Wells, J. Behr, U. Costabel, V. Cottin and V. Poletti.Eur Respir J2012; 39: 805–806.